5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

Page 5 of 5

1. GH Research PLC (NASDAQ:GHRS)

Biotechnology Value Fund’s Stake Value: $201 million

Percentage of Biotechnology Value Fund’s 13F Portfolio: 7.55% 

Number of Hedge Fund Holders: 27

Biotechnology Value Fund initiated a new position in GH Research PLC (NASDAQ:GHRS) during the second quarter of 2021. Debuted on NASDAQ in June 2021, shares of GH Research experienced a lot of volatility in the past couple of months. Mark Lampert’s fund held 9.2 million shares of depression drug-focused company. 

You can also take a look at Extreme Dividend Stocks With Upside Potential and 10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital.

Page 5 of 5